MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 3, 1998, Pages 194-200

  Inutsuka, Sadaaki ^a,b   Baba, Hideo ^a,b   Maehara, Yoshihiko ^a,b   Sugimachi, Keizo ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Anthracyclines; Combination Index; MST 16

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; 3' DEAMINO 2' FLUORO 3' HYDROXYDOXORUBICIN 14 PIMELATE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; MENOGARIL; PIPERAZINE DERIVATIVE; RAZOXANE; SOBUZOXANE; THERARUBICIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G2 PHASE; CYTOTOXICITY; DRUG POTENTIATION; DRUG UPTAKE; FEMALE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CELL DIVISION; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; MICE; MICE, INBRED BALB C; PIPERAZINES; TUMOR CELLS, CULTURED;

EID: 0031869875     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050805     Document Type: Article

References (27)

1. Ohno R, Masaoka T, Shirakawa S, Sakamoto S, Hirano M, Hanada S, Yasunaga K, Yokomaku S, Mitomo Y, Nagai K, Yamada K, Furue H, for the MST-16 Study Group (1993) Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). Cancer 71: 2217
2. Narita T, Koide Y, Yaguchi S, Kimura S, Izumisawa Y, Takase M, Inaha M, Tsukagoshi S (1991) Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine). Cancer Chemother Pharmacol 28: 235
3. Perkins WE, Schroeder RL, Carrano RA, Imondi AR (1982) Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br J Cancer 46: 662
4. Speyer JL, Green MD, Sanger J, Zeleniuch-Jacquotte A, Kramer E, Rev M, Wernz JC, Blum RH, Hochester H, Meyers M, Muggia FM (1990) A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 17: 161
5. Baba H, Stephens LC, Strebel FR, Siddik ZH, Newman RA, Ohno S, Bull JM (1991) Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Cancer Res 51: 3568
6. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacqotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319: 745
7. Myers C (1987) Anthracyclines. In: Pinedo HM, Longo DL, Chabner BA (eds) Cancer chemotherapy and biological response modifiers, Annal 9. Elsevier Science Publishers, p 36
8. Hurteloup P, Ganina F (1986) Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin. Drugs Exp Clin Res 12: 233
9. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4′-Ο-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42: 1462
10. Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4′-Ο- tetrahydropyranyladriamycin. J Antibiot 36: 312
11. Tone H, Hirano S, Shirai M, Kumagai H, Okajinia Y, Wakahayashi T (1986) Effect of (2″R)-4′-Ο-tetrahydropyranyladriamycin. a new antitumor antibiotic, on the cardiac function of hamsters. Jpn J Antihiot 39: 547
12. Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y (1989) A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and multidrug-resistant sublines. Cancer Res 49: 5537
13. Young CW, Raymond V (1986) Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep 70: 51
14. Weis GR, Brown TD, Kuhn JG, Von Hoff DD, Earhart RH, Adams WJ, Brewer JE, Hosley JD, Kasunic DA (1993) A phase I clinical and pharmacokinetic study of the oral and the oral/ intravenous administration of menogaril. Invest New Drugs 11: 17
15. Stewart DJ, Hugenholtz H, DaSilva VF, Benoit BG, Richard MT, Verma S, Earhart R, Robillard L (1992) Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults. J Neurooncol 13: 183
16. Chou TC, Talalay P (1987) Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapentic agents. Bristol-Meyers Cancer Symposia 8: 37
17. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27
18. Stark G, Stark U, Samonigg H, Kasparek K, Lueger A, Nagl S, Bertuch H, Pilger E, Tritthart HA (1990) Comparison of acute effects of anthracyclines on cardiac electrophysiological parameters of isolated guinea-pig hearts. Cancer Chemother Pharmacol 26: 415
19. Samonigg H, Kasparek AK, Stöger H, Schmid M, Eber B, Stark G, Weinrauch V, Pfeiffer K, Smola M, Steindorfer P, Lechner P (1990) 4′-Ο-tetrahydropyranyl-doxorubicin in advanced breast cancer: phase II study. Cancer Chemother Pharmacol 26: 293
20. Nishiyama M, Horichi N, Mazouzi Z, Bungo M, Saijo N, Tapiero H (1990) Can cytotoxic activity of anthracyclines be related to DNA damage? Anticancer Drug Design 5: 135
21. Tanabe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives Cancer Res 51: 4903
22. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T (1991) Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909
23. Skladanowski A, Konopa J (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem Pharmacol 46: 375
24. Liu YP, Araya S, Nakamura T (1992) Arrest in late G2 or prophase of cell cycle induced by 4,4-(1,2-ethanediyl) bis (1-isohutoxycarbonyloxymethyl 2,6-piperazinedione) (MST-16) in cultured L1210 cells. Int J Cancer 51: 792
25. Tarasiuk J, Foucrier J, Granier-Suillerot A (1993) Cell cycle dependent uptake and release of anthracycline by drug-resistant and drug-sensitive human leukemia K562 cells. Biochem Pharmacol 45: 1801
26. Minderman H, Linssen P, Weissels J, Hannen C (1993) Cell cycle related uptake, retention and loxicity of idarubicin, daunorubicin and doxorubicin. Anticancer Res 13: 1161
27. Wadler S, Green MD, Basch R, Muggia FM (1987) Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, ( + )-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF-187) on murine sarcoma S180 in vitro. Biochem Pharmacol 36: 1495